224 related articles for article (PubMed ID: 25212199)
21. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
Padmapriyadarsini C; Sekar L; Reddy D; Chitra A; Poornagangadevi N; Selvaraj M; Bhavani PK; Mothi SN; Nandagopal K; Vennila S; Tamizhselvan M; Maheshmanisha J; Agarwal U; Rewari BB; Swaminathan S
Indian J Med Res; 2020 Dec; 152(6):648-655. PubMed ID: 34145105
[TBL] [Abstract][Full Text] [Related]
22. Isoniazid preventive therapy programmes for healthcare workers in India: translating evidence into policy.
Raj R; Prasad H; Arya BK; Bhattacharya SD
Natl Med J India; 2011; 24(4):201-7. PubMed ID: 22208138
[TBL] [Abstract][Full Text] [Related]
23. Health system barriers to implementation of TB preventive strategies in South African primary care facilities.
Van Ginderdeuren E; Bassett J; Hanrahan C; Mutunga L; Van Rie A
PLoS One; 2019; 14(2):e0212035. PubMed ID: 30763378
[TBL] [Abstract][Full Text] [Related]
24. Treatment of latent tuberculosis infection in HIV infected persons.
Akolo C; Adetifa I; Shepperd S; Volmink J
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
[TBL] [Abstract][Full Text] [Related]
25. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
[TBL] [Abstract][Full Text] [Related]
26. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
[TBL] [Abstract][Full Text] [Related]
27. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Durovni B; Cavalcante SC; Saraceni V; Vellozo V; Israel G; King BS; Cohn S; Efron A; Pacheco AG; Moulton LH; Chaisson RE; Golub JE
AIDS; 2010 Nov; 24 Suppl 5(Suppl 5):S49-56. PubMed ID: 21079428
[TBL] [Abstract][Full Text] [Related]
28. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.
Golub JE; Cohn S; Saraceni V; Cavalcante SC; Pacheco AG; Moulton LH; Durovni B; Chaisson RE
Clin Infect Dis; 2015 Feb; 60(4):639-45. PubMed ID: 25365974
[TBL] [Abstract][Full Text] [Related]
29. Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study.
Johnson JL; Geldenhuys H; Thiel BA; Toefy A; Suliman S; Pienaar B; Chheng P; Scriba T; Boom WH; Hanekom W; Hatherill M
Chest; 2014 Mar; 145(3):612-7. PubMed ID: 24135768
[TBL] [Abstract][Full Text] [Related]
30. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
32. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients.
Khawcharoenporn T; Apisarnthanarak A; Manosuthi W; Sungkanuparph S; Mundy LM
Int J Tuberc Lung Dis; 2012; 16(3):336-41. PubMed ID: 22230143
[TBL] [Abstract][Full Text] [Related]
33. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
[TBL] [Abstract][Full Text] [Related]
34. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.
Otero L; Battaglioli T; Ríos J; De la Torre Z; Trocones N; Ordoñez C; Seas C; Van der Stuyft P
Trop Med Int Health; 2020 Mar; 25(3):346-356. PubMed ID: 31758837
[TBL] [Abstract][Full Text] [Related]
35. Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.
Huerga H; Mueller Y; Ferlazzo G; Mpala Q; Bevilacqua P; Vasquez B; Noël Mekiedje C; Ouattara A; Mchunu G; Weyenga HO; Varaine F; Bonnet M
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):e89-95. PubMed ID: 26910386
[TBL] [Abstract][Full Text] [Related]
36. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
Frigati LJ; Kranzer K; Cotton MF; Schaaf HS; Lombard CJ; Zar HJ
Thorax; 2011 Jun; 66(6):496-501. PubMed ID: 21460373
[TBL] [Abstract][Full Text] [Related]
37. Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts.
Assefa DG; Zeleke ED; Bekele D; Ejigu DA; Molla W; Woldesenbet TT; Aynalem A; Abebe M; Mebratu A; Manyazewal T
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612942
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Kim HY; Hanrahan CF; Martinson N; Golub JE; Dowdy DW
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1435-1442. PubMed ID: 30606315
[TBL] [Abstract][Full Text] [Related]
39. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Golub JE; Saraceni V; Cavalcante SC; Pacheco AG; Moulton LH; King BS; Efron A; Moore RD; Chaisson RE; Durovni B
AIDS; 2007 Jul; 21(11):1441-8. PubMed ID: 17589190
[TBL] [Abstract][Full Text] [Related]
40. Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa.
Page-Shipp L; Lewis JJ; Velen K; Senoge S; Zishiri E; Popane F; Chihota VN; Clark D; Churchyard GJ; Charalambous S
PLoS One; 2018; 13(3):e0192089. PubMed ID: 29499060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
